-
Founded in:
2004-08-09 -
Country:
China -
Address:
No. 176, Shenbei Road, Huishan Economic Development Zone, Shenbei New District, Shenyang -
Tax NO.:
91210100764362386F -
Registered Funds:
115 million yuan -
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Piroxicam |
It is a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic effects. This product exerts its pharmacological effects by inhibiting cyclooxygenase, reducing the synthesis of prostaglandins in local tissues, inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes.
More
It is a non-steroidal anti-inflammatory drug with analgesic, anti-inflammatory and antipyretic effects. This product exerts its pharmacological effects by inhibiting cyclooxygenase, reducing the synthesis of prostaglandins in local tissues, inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. |
36322-90-4 | 33 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Betahistine dihydrochloride |
It has a significant dilating effect on cerebrovascular and cardiovascular systems, especially on the vertebral artery system, significantly increasing the blood flow to the heart, brain and peripheral circulation, improving blood circulation, and lowering systemic blood pressure. In addition, it can increase the blood flow to the cochlea and anterior base, thereby eliminating inner ear vertigo, tinnitus and ear closure, and can also increase capillary permeability, promote the absorption of extracellular fluid, and eliminate lymphatic edema; it can counteract the vasoconstrictive effect of catecholamines and lower arterial pressure, and has an inhibitory effect on plasma coagulation and ADP-induced platelet aggregation, can prolong the time of thrombosis in vitro in rats, and has a slight diuretic effect.
More
It has a significant dilating effect on cerebrovascular and cardiovascular systems, especially on the vertebral artery system, significantly increasing the blood flow to the heart, brain and peripheral circulation, improving blood circulation, and lowering systemic blood pressure. In addition, it can increase the blood flow to the cochlea and anterior base, thereby eliminating inner ear vertigo, tinnitus and ear closure, and can also increase capillary permeability, promote the absorption of extracellular fluid, and eliminate lymphatic edema; it can counteract the vasoconstrictive effect of catecholamines and lower arterial pressure, and has an inhibitory effect on plasma coagulation and ADP-induced platelet aggregation, can prolong the time of thrombosis in vitro in rats, and has a slight diuretic effect. |
5579-84-0 | 21 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Indometacin |
It has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus.
More
It has anti-inflammatory, antipyretic and analgesic effects. Its mechanism of action is to reduce the synthesis of prostaglandins by inhibiting cyclooxygenase. It stops the formation of pain nerve impulses in inflammatory tissues and inhibits inflammatory reactions, including inhibiting the chemotaxis of leukocytes and the release of lysosomal enzymes. As for the antipyretic effect, it acts on the hypothalamic temperature regulation center, causing peripheral vasodilation and sweating, which increases heat dissipation. This central antipyretic effect may also be related to the inhibition of prostaglandin synthesis in the hypothalamus. |
53-86-1 | 23 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Carbamazepine |
Anticonvulsant, anti-epileptic, anti-neuropathic pain, anti-manic-depressive, improve symptoms of certain mental illnesses, anti-central diabetes insipidus. The mechanism may include: 1. Use-dependent blocking of various excitable cell membrane Na channels, inhibiting the occurrence and spread of abnormal high-frequency discharges; 2. Inhibition of T-type calcium channels; 3. Enhancement of the activity of central noradrenergic nerves; 4. Promoting the secretion of antidiuretic hormone (ADH) or increasing the sensitivity of effectors to ADH.
More
Anticonvulsant, anti-epileptic, anti-neuropathic pain, anti-manic-depressive, improve symptoms of certain mental illnesses, anti-central diabetes insipidus. The mechanism may include: 1. Use-dependent blocking of various excitable cell membrane Na channels, inhibiting the occurrence and spread of abnormal high-frequency discharges; 2. Inhibition of T-type calcium channels; 3. Enhancement of the activity of central noradrenergic nerves; 4. Promoting the secretion of antidiuretic hormone (ADH) or increasing the sensitivity of effectors to ADH. |
298-46-4 | 43 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Carbamazepine |
Anticonvulsant, anti-epileptic, anti-neuropathic pain, anti-manic-depressive, improve the symptoms of certain mental illnesses, and treat central diabetes insipidus. The mechanism may include use-dependent blocking of various excitable cell membrane Na channels, inhibition of T-type calcium channels, enhancement of central noradrenergic nerve activity, promotion of antidiuretic hormone (ADH) secretion, or increased sensitivity of effectors to ADH.
More
Anticonvulsant, anti-epileptic, anti-neuropathic pain, anti-manic-depressive, improve the symptoms of certain mental illnesses, and treat central diabetes insipidus. The mechanism may include use-dependent blocking of various excitable cell membrane Na channels, inhibition of T-type calcium channels, enhancement of central noradrenergic nerve activity, promotion of antidiuretic hormone (ADH) secretion, or increased sensitivity of effectors to ADH. |
298-46-4 | 43 |